Clinical trials have consistently shown an increased risk of serious infections and a possible rise in certain cancers compared to conventional disease-modifying antirheumatic drugs, likely due to its immunosuppressive effect on the JAK-STAT pathway.14 Here, SOAT1 is linked to cancer.